Lung Cancer: Liz's Survivor Story

Patient Info: Liz, Female, 40s

Liz’s localized lung cancer was treated with surgery, chemotherapy, and 6 weeks of radiotherapy; by January 2016 her follow-up assessment was clear.

EGFR Non-Small Cell Lung Cancer: Donna's Patient Story

Patient Info: Donna Thompson, Female, 40s

Biomarkers: EGFR-positive lung cancer reported during recurrence; initial tumor biomarker status not reported

Recurrent NSCLC after earlier Stage II surgery and limited chemotherapy; later EGFR-targeted therapy caused kidney failure, 2 new spots were radiated in July 2025, and new nodules are under watchful monitoring.

GO2 FoundationRead more →

Stage IV Non-Small Cell Lung Cancer: Usha's Patient Story

Patient Info: Usha Jain, Female | Stage IV

Biomarkers: Tumor genetic profile available for navigation review, but specific results are not reported

Stage IV NSCLC after nearly 2 years of chemotherapy and immunotherapy, followed by watchful monitoring with routine scans; clinical trials were reviewed but not pursued.

GO2 FoundationRead more →

Stage IV HER2-Positive Non-Small Cell Lung Cancer: Glenna's Survivor Story

Patient Info: Glenna, Female | Stage IV

Biomarkers: HER2 mutation confirmed by blood and tissue biopsy biomarker testing

Stage IV HER2-mutated NSCLC with first-line chemotherapy failure, then ongoing Enhertu from September 2023 and official NED/no evidence of disease status.

Lung Cancer Research FoundationRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Lexi's Patient Story

Patient Info: Lexi, Female, Under 40 | Stage IV

Biomarkers: EGFR exon 20 mutation

Metastatic Site: Bone — left leg and hip

Living with Stage IV EGFR exon 20 metastatic NSCLC involving bone, after chemotherapy, targeted therapy, a drug trial, and surgery to remove the primary lung mass; latest disease-control status is not clearly stated.

Lung Cancer Research FoundationRead more →

Stage III EGFR Non-Small Cell Lung Cancer: Lauren's Survivor Story

Patient Info: Lauren, Female, Under 40 | Stage III

Biomarkers: EGFR mutation

No evidence of cancer on 1-year scan after fertility preservation, chemotherapy, radiation, and removal of half the left lung for Stage III EGFR-mutated lung cancer.

Lung Cancer Research FoundationRead more →

EGFR Non-Small Cell Lung Cancer: Joanne's Patient Story

Patient Info: Joanne, Female, 60s

Biomarkers: EGFR exon deletion 19 mutation

Ongoing care after right upper-lobe resection, 4 rounds of chemotherapy, and daily Tagrisso for EGFR exon 19 deletion lung adenocarcinoma; formal stage is not stated in the story.

Lung Cancer Research FoundationRead more →

Stage III ROS1 Non-Small Cell Lung Cancer: Wendy's Survivor Story

Patient Info: Wendy, Female | Stage III

Biomarkers: ROS1-positive / ROS1-rearranged

Completed chemoradiation, surgery, and post-surgery radiation for Stage III ROS1-positive NSCLC by January 2017 and later shared a long-term survivor/advocacy story; no explicit NED statement is given.

Lung Cancer Research FoundationRead more →

Stage IV Lung Cancer: Karen's Patient Story

Patient Info: Karen, Female, 40s | Stage IV

Biomarkers: Rare mutation affecting about 3% of lung cancer patients; mutation not named

Metastatic Site: Rib/bone involvement reported through recurrent tumor…

More than 8 years after initial Stage II lung cancer, Karen had a Stage IV recurrence requiring removal of a tumor and 2 ribs; she remained active and hopeful, but ongoing targeted treatment is not specifically stated.

Lung Cancer Research FoundationRead more →

Laura Greco: Stage IV Lung Cancer

Patient Info: Laura Greco, Female | Stage IV

Biomarkers: ALK translocation / ALK-driven; MET amplification; EGFR amplification reported in brain tumor

Metastatic Site: Brain

Laura Greco passed away on July 14, 2024 after Stage IIIA ALK-driven lung cancer later metastasized to the brain and required repeated brain-directed treatment and targeted therapy.

Lung Cancer Research FoundationRead more →

Stage IV Lung Cancer: Mila's Patient Story

Patient Info: Mila Gardon, Female, 50s | Stage IV

Metastatic Site: Neck lymph nodes; skull; iliac bone

Stage IV lung cancer with spread to neck lymph nodes, skull, and iliac bone responded after cryotherapy and interventional therapy; lung tumors disappeared and tumor marker normalized, but the source does not state full remission or NED.

Stage IV ALK Non-Small Cell Lung Cancer: Linnea's Patient Story

Patient Info: Linnea Olson, Female, 40s | Stage IV

Biomarkers: ALK mutation / ALK-rearranged lung cancer

Metastatic Site: Lungs / intrapulmonary disease

Living long term with Stage IV ALK-positive NSCLC; ALK-targeted clinical trials controlled disease for years but were described as disease control rather than cure.

Massachusetts General HospitalRead more →

Stage III Lung Adenocarcinoma: Becky's Survivor Story

Patient Info: Becky Manning, Female, 40s | Stage III

After surgery, chemotherapy and 8 months of nivolumab on a clinical trial, Becky was no longer on active treatment, had no evidence of disease, felt well, and returned to MSK every 6 months for follow-up.

Memorial Sloan KetteringRead more →

Delayed adrenal insufficiency after lung cancer immunotherapy

Patient Info: Anonymized, male, 60s | Stage II

Imaging and bronchoscopy in November 2024 showed no lung-cancer recurrence or metastasis. By June 2026, he had not experienced another adrenal crisis while continuing hormone replacement.

PubMed CentralRead more →

A man with lung cancer develops kidney and lung side effects during durvalumab treatment

Patient Info: Anonymized, Male, 60s

Alive at 200 weeks with sustained improvement in proteinuria and kidney injury after durvalumab was discontinued.

PubMed CentralRead more →

More than 5 years living with metastatic lung adenocarcinoma after stepwise molecular testing

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: HER2 amplification, EGFR L858R mutation, PD-L1 <1%

Metastatic Site: brain, lung

As of April 2026, she remained on gefitinib with no active tumor lesions after complete regression of lung metastases, more than 5 years (66 months) after her original diagnosis.

PubMed CentralRead more →

Severe blood-clotting disorder, liver injury, and reversible kidney injury during treatment for Stage IV lung cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1 about 1%; KRAS mutation

Metastatic Site: bone (right 4th and 5th ribs)

Restaging before cycle 4 showed a partial response. Cancer treatment was then interrupted as severe acquired iTTP, cholestatic liver injury, and reversible acute kidney injury required intensive management.

PubMed CentralRead more →

Lung cancer first discovered after a small-bowel blockage

Patient Info: Anonymized, Male, 50s | Stage IV

Metastatic Site: jejunum|brain|bone

The cancer progressed to the brain and spine despite chemotherapy, and he was admitted to palliative care.

PubMed CentralRead more →

Stage IIIB lung cancer: heart inflammation from durvalumab immunotherapy, mistaken at first for tumor spreading to the heart

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: No actionable driver mutations identified; PD-L1 tumor proportion score <1%

She recovered cardiac function after treatment for durvalumab-associated myocarditis and remained without lung-cancer relapse or cardiac decline for more than 4 years, with no additional anticancer therapy.

PubMed CentralRead more →

Long-term lung cancer control after immunotherapy-related diabetes

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 80%; EGFR, ALK, ROS1 and BRAF negative

Metastatic Site: brain|liver

After years of disease control off pembrolizumab, a new brain lesion appeared in December 2025 and was treated with focused radiation. He remained clinically stable under oncology follow-up.

PubMed CentralRead more →

Whole-liver radiation for Stage IV small cell lung cancer with diffuse liver metastases

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: liver, bone

After renewed liver progression and declining performance status, chemotherapy was stopped and supportive care began. He died in a palliative care unit on July 27, 2019.

PubMed CentralRead more →

Lung adenocarcinoma that spread to the thyroid 9 years later

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: thyroid

After the thyroid metastasis was removed, she started systemic chemotherapy and remained under oncology management.

PubMed CentralRead more →

Long-term lung cancer response complicated by immune-related lung inflammation

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: KRAS mutation; PD-L1 90%

Metastatic Site: pleura|lungs|peritoneum|bone|brain

By October 2025, the lung inflammation had resolved and she remained in systemic and intracranial remission.

PubMed CentralRead more →

HER2-mutated lung cancer: restarting targeted therapy after lung inflammation

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: HER2 exon 20 insertion; PD-L1 negative

Metastatic Site: brain

Trastuzumab deruxtecan was restarted successfully after lung inflammation improved, but it was discontinued after 9 cycles when the cancer progressed.

PubMed CentralRead more →